Table 3.
Treatment Exposures Associated With Latent Class Membership: CRT
| Variable | Internalizing Versus Well Adjusted | Global Symptoms Versus Well Adjusted | ||
|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |
| Age, years | ||||
| At diagnosis | 0.9 | 0.9 to 1.0 | 1.0 | 0.9 to 1.2 |
| At survey | ||||
| 12-14 | 0.9 | 0.7 to 1.2 | 1.8 | 1.0 to 3.2 |
| 15-17 | 1.0 | 1.0 | ||
| Sex | ||||
| Female | 1.0 | 1.0 | ||
| Male | 0.9 | 0.6 to 1.1 | 1.1 | 0.6 to 1.8 |
| Race/ethnicity | ||||
| White | 1.0 | 1.0 | ||
| Black | 1.2 | 0.6 to 2.2 | 2.3 | 0.9 to 5.8 |
| Other | 1.3 | 0.8 to 2.0 | 1.2 | 0.5 to 3.0 |
| CRT, Gy | ||||
| < 30 | 1.0 | 1.0 | ||
| ≥ 30 | 1.7 | 1.0 to 2.8 | 3.2 | 1.2 to 8.4 |
| IT methotrexate, mg/m2 | ||||
| None | 1.0 | 1.0 | ||
| < 230 | 0.9 | 0.5 to 1.6 | 2.2 | 0.7 to 6.9 |
| ≥ 230 | 1.3 | 0.7 to 2.3 | 3.2 | 0.9 to 11.9 |
| IV methotrexate | ||||
| No | 1.0 | 1.0 | ||
| Yes | 1.2 | 0.8 to 1.8 | 1.7 | 0.8 to 3.8 |
| Cytarabine | ||||
| No | 1.0 | 1.0 | ||
| Yes | 0.8 | 0.5 to 1.3 | 0.4 | 0.2 to 1.2 |
| Corticosteroids | ||||
| None | 1.0 | 1.0 | ||
| Nondexamethasone | 1.2 | 0.7 to 2.0 | 1.0 | 0.4 to 2.8 |
| Dexamethasone | 1.0 | 0.6 to 1.7 | 1.3 | 0.5 to 3.3 |
| Anthracyclines, mg/m2 | ||||
| None | 1.0 | 1.0 | ||
| < 300 | 1.0 | 0.7 to 1.6 | 0.9 | 0.4 to 2.3 |
| ≥ 300 | 1.9 | 1.2 to 3.0 | 1.8 | 0.7 to 4.3 |
NOTE. In all, 979 participants were included in this analysis.
Abbreviations: CRT, cranial radiation therapy; IT, intrathecal; IV, intravenous; OR, odds ratio.